A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma
{{output}}
Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy. ... ...
